Clinical Update on the Use of Moxifloxacin in the Treatment of Community-Acquired Complicated Intraabdominal Infections
dc.contributor.author | Cheadle, William G. | en_US |
dc.contributor.author | Lee, James T. | en_US |
dc.contributor.author | Napolitano, Lena M. | en_US |
dc.contributor.author | Nichols, Ronald Lee | en_US |
dc.date.accessioned | 2011-06-17T20:27:09Z | |
dc.date.available | 2011-06-17T20:27:09Z | |
dc.date.issued | 2010 | en_US |
dc.identifier.citation | Cheadle, William; Lee, James T.; Napolitano, Lena M.; Nichols, Ronald Lee (2010/06/29). "Clinical Update on the Use of Moxifloxacin in the Treatment of Community-Acquired Complicated Intraabdominal Infections." Surgical Infections, 11(5): 487-494 <http://hdl.handle.net/2027.42/85118> | en_US |
dc.identifier.issn | 1096-2964 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/85118 | |
dc.description.abstract | Abstract Background: Community-acquired complicated intraabdominal infections (cIAIs) present problems for clinicians and have substantial impact on hospital resources. Because of the polymicrobial nature of these infections, successful management of cIAIs depends on timely and appropriate use of antisepsis and antiinfective strategies. Methods: The literature pertinent to this article was reviewed. Results: The Surgical Infection Society and the Infectious Disease Society of America guidelines recommend a variety of single and combined antimicrobial therapies, including fluoroquinolone therapy, for prophylactic and definitive treatment of cIAIs with different severities. Moxifloxacin, a fluoroquinolone, demonstrates a broad spectrum of antimicrobial (including anaerobic) activity, good tissue penetration into the gastrointestinal tract, and a good tolerability profile. Clinical data also have demonstrated that moxifloxacin is effective as monotherapy for patients with cIAIs. This review identifies the clinical issues impacting antimicrobial selection in cIAI and discusses data on the role of moxifloxacin in light of the current guidelines for management of these patients. Conclusion: Moxifloxacin provides clinicians with a convenient monotherapy option for the treatment of mild-to-moderate cIAIs. | en_US |
dc.publisher | Mary Ann Liebert, Inc., publishers | en_US |
dc.title | Clinical Update on the Use of Moxifloxacin in the Treatment of Community-Acquired Complicated Intraabdominal Infections | en_US |
dc.type | Article | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.identifier.pmid | 20583956 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/85118/1/sur_2009_062.pdf | |
dc.identifier.doi | 10.1089/sur.2009.062 | en_US |
dc.identifier.source | Surgical Infections | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.